Skip to content

Alto Neuroscience ANRO Debt Repayments

Debt Repayments at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$70M
Medtronic logo
MedtronicMDT
$1.77B
Arrowhead Research logo
Arrowhead ResearchARWR
$17.83M-88.2%
Revvity logo
RevvityRVTY
$0+100%
Stryker logo
StrykerSYK
$1B
Opko Health logo
Opko HealthOPK
$8.88M-7.0%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's debt repayments?
Alto Neuroscience (ANRO) reported debt repayments of $0 in Q1 2026.
How has Alto Neuroscience's debt repayments changed year-over-year?
Alto Neuroscience's debt repayments decreased by 100.0% year-over-year, from $10.21M to $0.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.